Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2724559 | 0.93 | CSF1R (0.58) | CSF1RNUDT1 | |
| SCHEMBL5929884 | 0.90 | CSF1R (0.56) | CSF1RNUDT1 | |
| SCHEMBL3864556 | 0.89 | CSF1R (0.55) | CSF1RNUDT1 | |
| SCHEMBL31554519 | 0.87 | EGFR (0.58) | CSF1RNUDT1 | |
| SCHEMBL7165177 | 0.87 | EGFR (0.58) | CSF1RNUDT1 | |
| SCHEMBL13915596 | 0.86 | CSF1R (0.57) | CSF1RNUDT1 | |
| SCHEMBL5929634 | 0.86 | CSF1R (0.57) | CSF1RNUDT1 | |
| SCHEMBL5929704 | 0.86 | CSF1R (0.57) | CSF1RNUDT1 | |
| SCHEMBL4915671 | 0.86 | CSF1R (0.49) | CSF1RNUDT1 | |
| SCHEMBL15054612 | 0.82 | CSF1R (0.47) | CSF1RNUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| CN-1286815-C | 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-11-29 | — | — | CN | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| US-7037925-B2 | 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-05-02 | — | — | US | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
| US-20040248923-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | disclosed |
| CN-1507434-A | Novel 4-anilinoquinoline-3-carboxamides | — | 2004-06-23 | — | — | CN | disclosed |
| EP-1387830-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092571-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | CSF1R 237/4885NUDT1 318/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | CSF1R 237/4885NUDT1 318/4885 |
| US-20040248923-A1 | Novel 4-anilinoquinoline-3-carboxamides | JAK3, JAK2, JAK1 | CSF1R 637/4885NUDT1 3959/4885 |
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | JAK3, JAK2, JAK1 | CSF1R 889/4885NUDT1 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.